GCP
ALNY icon

Garda Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Garda Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,143
Closed -$2.09M – 623
2024
Q4 		$1.92M Buy
+8,143
New +$2.14M 0.14% 124

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Garda Capital Partners's ALNY Position: Q1 2025 in Review

Garda Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 8,143 shares — an estimated $2.09M sold.

Garda Capital Partners first reported a position in ALNY in Q4 2024 and held it in 1 quarter. The position peaked at $1.92M in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Garda Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Garda Capital Partners sold 8,143 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $2.09M.
  • Garda Capital Partners first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Garda Capital Partners's Alnylam Pharmaceuticals position peaked at $1.92M in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Garda Capital Partners's 13F filing for Q1 2025, filed 14 May 2025.